Gubra AS (STU:PI3) Price-to-Funds-From-Operations: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PI3 Gubra AS STU:PI3
72 GF Score
Price €41.92
GF Value €26.48
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Gubra AS Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

STU:PI3
72GF Score
Gubra AS STU:PI3
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gubra AS (STU:PI3) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be overvalued. The current stock price of €41.92 is trading 58.3% above its estimated GF Value™ of €26.48. GuruFocus considers Gubra AS to be Significantly Overvalued.

Key valuation signals for STU:PI3:

  • Price-to-Funds-From-Operations:
  • GF Value™: €26.48 vs. price of €41.92 (58.3% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gubra AS Business Description

Other Exchanges GUBRA:Denmark
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
72GF Score

Get the complete analysis for STU:PI3

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.92
Price
€26.48
GF Value